. 2013 Oct 18;79(1):56–71. doi: 10.1111/bcp.12258

Table 2.

Population analyses of clinical tumour marker response

Tumour type	Treatment	PD measurement (s)	Driver of PD response	Model type	Predictors for survival		Reference
Tumour type	Treatment	PD measurement (s)	Driver of PD response	Model type	Model-based	Other	Reference
Prostate	Prostatectomy	PSA	None	Two compartment	CL_PSA ^(*)	–	You et al., 2009 [36]
NSGCT	Bleomycin, etoposide, cisplatin	AFP	None	One compartment	AUC_AFG-hCG ^(*)	–	You et al., 2010 [37]
NSGCT	Bleomycin, etoposide, cisplatin	hCG	None	One compartment	AUC_AFG-hCG ^(*)	–	You et al., 2010 [37]
Multiple myeloma	Dexamethasone	M-protein	Dose	TGI	–	–	Jonsson et al., 2010 [38]
Ovarian	C/P; carboplatin/pegylated liposomal doxorubicin	CA-125	Tumour(t)	IDR III	–	–	Wilbaux et al., 2011 [39]

AFP, alpha fetoprotein; AUC, area under the concentration curve; C/P, carboplatin/paclitaxel; CA125, cancer antigen 125; CL, clearance; hCG, human chorionic gonadotropin; IDR, indirect response model; NSGCT, non-seminomatous germ cell tumour; PD, pharmacodynamics; PSA, prostate-specific antigen; TGI, tumour growth inhibition model.

^(*)

Survival analysis was performed using non-parametric methods.